繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Aadi Bioscience Shares Fall as Tumor Treatment Trial Halted; Job Cuts Planned

2024-08-21 05:59

05:59 PM EDT, 08/20/2024 (MT Newswires) -- Aadi Bioscience (AADI) shares fell 27% in after-hours trading Tuesday after the company said its Precision1 trial of nab-sirolimus in cancer patients is unlikely to meet the efficacy threshold for regulatory approval.

The company said it decided to halt the tumor-agnostic therapy trial and will instead focus on marketing Fyarro, its treatment for patients with advanced malignant perivascular epithelioid cell tumor.

Aadi said it will reduce its research and development workforce by 80%.

"Together these actions extend cash runway into at least" H2 2026, the company said.

"Aadi will now focus on preserving cash while maximizing its commercial business," according to a statement. Fyarro generated $6.2 million in sales in Q2, the company said.

The company said while new patient enrollment will be halted, dosing of previously enrolled patients will continue in two ongoing phase 2 trials of nab-sirolimus for advanced or recurrent endometrioid-type endometrial cancer and neuroendocrine tumors.

Price: 1.1900, Change: -0.43, Percent Change: -26.54

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。